Literature DB >> 19523922

Synthetic oligoribonucleotides-containing secondary structures act as agonists of Toll-like receptors 7 and 8.

Tao Lan1, Mallikarjuna Reddy Putta, Daqing Wang, Meiru Dai, Dong Yu, Ekambar R Kandimalla, Sudhir Agrawal.   

Abstract

Single-stranded RNAs act as ligands of Toll-like receptors (TLRs) 7 and 8 and induce immune responses. In the present study, we have designed and synthesized phosphorothioate oligoribonucleotides (ORNs) with self-complementary sequences that form duplex structures with either 3'- or 5'-overhanging sequences. We studied the new ORNs for their duplex formation, nuclease stability, and ability to induce immune-stimulatory activate through TLR7 and TLR8 in TLR-transfected cell lines, human PBMCs, human pDCs, and in vivo in mice. Thermal melting and gel electrophoresis studies showed that all ORNs formed secondary structures and that the thermal stability of the duplex is depended on the length and GC composition of the duplex. Nuclease stability of ORNs increased with increasing thermal stability of the duplex formed. All ORN showed TLR8 activity in HEK293 cells, and induced cytokine and chemokine production in human PBMC cultures. In addition to TLR8 activity, two ORNs containing a 'CUGAAUU' motif in the duplex-forming region induced immune stimulation through TLR7 in HEK293 cells, human PBMC and pDC cultures, and in vivo in mice. These results suggest that secondary structures in ORN provide nuclease stability and lead to stimulation of immune responses through TLR8 as well as TLR7 depending on the presence of specific nucleotide motifs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19523922     DOI: 10.1016/j.bbrc.2009.06.036

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs.

Authors:  Pinal C Patel; Liangliang Hao; Weng Si Au Yeung; Chad A Mirkin
Journal:  Mol Pharm       Date:  2011-06-28       Impact factor: 4.939

2.  Specific gene silencing using RNAi in cell culture.

Authors:  Chunxing Yang; Linghua Qiu; Zuoshang Xu
Journal:  Methods Mol Biol       Date:  2011

Review 3.  Precise and efficient siRNA design: a key point in competent gene silencing.

Authors:  E Fakhr; F Zare; L Teimoori-Toolabi
Journal:  Cancer Gene Ther       Date:  2016-03-18       Impact factor: 5.987

4.  TRPC3 channels critically regulate hippocampal excitability and contextual fear memory.

Authors:  Sarah M Neuner; Lynda A Wilmott; Kevin A Hope; Brian Hoffmann; Jayhong A Chong; Joel Abramowitz; Lutz Birnbaumer; Kristen M O'Connell; Andrew K Tryba; Andrew S Greene; C Savio Chan; Catherine C Kaczorowski
Journal:  Behav Brain Res       Date:  2014-12-13       Impact factor: 3.332

Review 5.  Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors.

Authors:  Sudhir Agrawal; Ekambar R Kandimalla
Journal:  Immunooncol Technol       Date:  2019-10-16

6.  Plasmacytoid dendritic cell interferon-α production to R-848 stimulation is decreased in male infants.

Authors:  Jennifer P Wang; Lei Zhang; Rachel F Madera; Marcia Woda; Daniel H Libraty
Journal:  BMC Immunol       Date:  2012-07-06       Impact factor: 3.615

Review 7.  RNA mediated Toll-like receptor stimulation in health and disease.

Authors:  Alexander Dalpke; Mark Helm
Journal:  RNA Biol       Date:  2012-05-23       Impact factor: 4.652

Review 8.  The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey.

Authors:  Sudhir Agrawal
Journal:  Biomedicines       Date:  2021-05-03

9.  A modified dinucleotide motif specifies tRNA recognition by TLR7.

Authors:  Steffen Kaiser; Katharina Rimbach; Tatjana Eigenbrod; Alexander H Dalpke; Mark Helm
Journal:  RNA       Date:  2014-07-22       Impact factor: 4.942

10.  siRNA Design to Silence the 3'UTR Region of Zika Virus.

Authors:  María Perez-Mendez; Paola Zárate-Segura; Juan Salas-Benito; Fernando Bastida-González
Journal:  Biomed Res Int       Date:  2020-08-02       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.